ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Core Viewpoint - ARS Pharmaceuticals, Inc. is set to host a conference call and webcast on August 13, 2025, to discuss its Q2 2025 financial results and business highlights [1] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and their caregivers to protect against allergic reactions that may lead to anaphylaxis [3] - The company is commercializing neffy® (EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 15 kg in the U.S. and for patients weighing at least 30 kg in the EU [3]